Quick Facts: Uses and Benefits

• Aids in the management of primary carnitine deficiency.
• Used for the acute and chronic treatment of secondary carnitine deficiency in individuals with inborn errors of metabolism.
• Intended for the prevention and care of carnitine deficiency in patients with end-stage renal disease who are undergoing hemodialysis.

---

What Карнифит Treats

Карнифит (Levocarnitine) is administered in specific clinical situations where a deficiency of carnitine is present. It is designated to assist in addressing this deficiency, which can arise from certain genetic disorders or medical conditions.

The medication is utilized in the management of primary systemic carnitine deficiency. This condition involves abnormally low levels of carnitine in the body, which may be associated with symptoms like hypotonia (reduced muscle tone) and muscle weakness. When used in these situations, the administration of Levocarnitine may contribute to the relief of related signs and symptoms.

Карнифит is also indicated for the acute and ongoing care of individuals with an inborn error of metabolism that leads to a secondary carnitine deficiency. Additionally, it serves to prevent or manage carnitine deficiency that often arises in patients with end-stage renal disease who receive maintenance hemodialysis. In this patient group, intervention with Levocarnitine may support the maintenance of adequate carnitine levels in the body, which is important for energy production.

Who Can and Cannot Use Карнифит (Levocarnitine)

The eligibility for using Levocarnitine is strictly defined by official regulatory documentation, covering approved populations and formal exclusions.

Allowed Populations and Age Groups

The medicine is approved for patients with primary systemic carnitine deficiency and secondary carnitine deficiency resulting from inborn errors of metabolism. The injectable formulation is also approved for patients with end-stage renal disease (ESRD) undergoing hemodialysis. The eligibility profile includes pediatric patients, and official labeling notes that use in older adults is not expected to present different problems compared to younger adults.

Absolute Contraindications and Major Restrictions

Use is formally contraindicated in patients with a known hypersensitivity to levocarnitine or any component of the formulation. Additionally, the oral solution and tablets are not recommended for long-term chronic administration in patients with severe renal impairment or ESRD, as this may lead to the accumulation of potentially toxic metabolites.

Conditional Use Status

Caution is required for patients with pre-existing seizure activity, as there are reports of an increase in seizure frequency and/or severity. For pregnant women, use is restricted to situations where it is clearly needed (FDA Category B) due to the absence of adequate human safety studies. During lactation, the risks to the infant must be carefully weighed against the maternal benefit, with consideration given to discontinuing either nursing or treatment.

Interactions with other medicines and products

Official regulatory information for Levocarnitine (the active substance in Карнифит) documents several clinically relevant interactions, focusing primarily on exposure modification and pharmacodynamic effects.

---

Documented Pharmacodynamic Interaction

Levocarnitine has been reported to potentiate the effects of coumarin anticoagulants, such as warfarin and acenocoumarol. This interaction can lead to an increase in the International Normalized Ratio (INR).

Constraint: Patients initiating or adjusting their Levocarnitine dosage while taking anticoagulants require increased INR monitoring to manage the potential for enhanced hypoprothrombinemic effects.

---

Exposure-Modifying Substances

Several anticonvulsants are officially associated with altered carnitine status. Medicines like valproic acid, carbamazepine, phenytoin, and phenobarbital may lead to a decrease in endogenous carnitine levels within the body.

Drugs that modify renal function, such as acetazolamide, may increase the excretion rate of Levocarnitine, potentially lowering its serum concentration.

---

Population-Specific Constraint

Patients with severely compromised renal function (e.g., End-Stage Renal Disease on dialysis) have a specific safety concern tied to oral administration. Chronic high-dose use can lead to the accumulation of metabolites (trimethylamine and trimethylamine-N-oxide), which are typically excreted by the kidneys.

Карнифит, which contains L-carnitine, functions as a critical cofactor in intermediary metabolism, particularly within tissues with high fatty acid oxidative capacity, such as skeletal and cardiac muscle. Its primary biological target is the mitochondrial membrane transport system, specifically the Carnitine Shuttle.

L-carnitine facilitates the transport of long-chain fatty acyl-Coenzyme A (CoA) from the cytosol into the mitochondrial matrix. This is accomplished through a series of enzymatic reactions:

1. Carnitine Palmitoyltransferase I (CPT I), located on the outer mitochondrial membrane, catalyzes the transfer of the long-chain acyl group from acyl-CoA to L-carnitine, forming a long-chain acylcarnitine (a condensation-type reaction).
2. The acylcarnitine is then translocated across the inner mitochondrial membrane by the Carnitine-Acylcarnitine Translocase (CACT).
3. Inside the matrix, Carnitine Palmitoyltransferase II (CPT II) catalyzes the reverse reaction, regenerating long-chain acyl-CoA and free L-carnitine, which is recycled.

This process is essential for the subsequent beta-oxidation of fatty acids within the matrix, a molecular pathway that generates acetyl-CoA. The downstream cascade includes the entry of acetyl-CoA into the Krebs cycle for the production of reducing equivalents, ultimately driving oxidative phosphorylation and the synthesis of Adenosine Triphosphate (ATP).

Furthermore, L-carnitine acts as an acyl-buffer, binding to excess short-chain acyl groups and regulating the free Coenzyme A pool within the mitochondria. The system-level physiological consequence is the modulation of cellular fuel substrate utilization toward fatty acid oxidation for energy production.

Administration and Dosing Principles

Карнифит (Levocarnitine) is administered through two primary routes: oral (using solution or tablets) for long-term management, and intravenous (IV) injection for acute care or deficiency related to hemodialysis. Regardless of the form, dosage is typically titrated (adjusted slowly) based on the therapeutic response and is intended to be a long-term treatment.

Oral Use Guidelines

Oral administration requires the total daily dose—which ranges up to 3 grams in adults—to be divided and taken in two or three evenly spaced portions. These doses must be consumed during or immediately following meals to enhance tolerability. The oral solution may be consumed alone or diluted in drinks or other liquid foods; in either case, it should be consumed slowly to maximize tolerance.

Intravenous Use for Dialysis

For patients with end-stage renal disease (ESRD) undergoing hemodialysis, the IV injection is the required route. The recommended starting dose is 10 to 20 mg/kg of dry body weight, administered as a slow 2 to 3-minute bolus injection into the venous return line after the completion of each dialysis session. The dose may be adjusted downward after several weeks, guided by laboratory monitoring.

Pediatric and Missed Dose Rules

Dosage for children is calculated based on body weight (mg/kg/day). If an oral dose is missed, the standard practice is to skip the missed dose and continue with the regular schedule; doses should not be doubled.

Research evidence / Overview of studies for Карнифит

---

Evidence for use in Chronic Insomnia

Research exploring the use of Карнифит for chronic insomnia has primarily focused on short-term randomized controlled trials (RCTs). These studies examined patient-reported experiences and monitored physiological strain. The main focus was on short-term outcomes related to systemic or functional imbalance, such as total sleep time and the time it took participants to fall asleep.

Studies report how symptoms evolved in the observed populations, describing patterns observed in the studies that showed differences in measurements of various sleep metrics when compared to a placebo group. These findings describe group patterns, not personal outcomes, and are based on data collected over a few weeks or months.

There is limited information for long-term outcomes, as follow-up durations were limited in the existing studies. Evidence is limited regarding the association between measured sleep parameters and outcomes reflecting daily functioning.

---

Evidence for use in Generalized Anxiety Disorder (GAD)

Research examined the use of Карнифит in conditions characterized by fluctuating manifestations through short- to intermediate-term randomized trials. Studies used standardized anxiety rating scales to measure outcomes related to systemic or functional imbalance.

Studies report how symptoms evolved in the observed populations, describing how measurements of the average scores on standardized anxiety scales differed in the groups that received the substance compared to placebo groups over the study period. This research provides context but not individual predictions.

Follow-up durations were limited, meaning that long-term effects are not fully established. Data for certain groups, such as those with severe GAD, remain insufficient.

---

Evidence for use in Fibromyalgia

Studies explored the substance in populations with fibromyalgia primarily through intermediate-term trials. Research examined outcomes related to physical discomfort and daily functioning.

Research highlights changes measured during the study period, reporting the proportion of participants in the study groups who were observed to meet the study-defined threshold compared to the proportion in the placebo groups. Variability was described regarding the reported patterns in other outcomes, such as general fatigue.

---

What is still Uncertain about Карнифит

A key limitation is that sample sizes were modest and the follow-up durations were limited across most indications, meaning certainty remains low regarding long-term effects. Variability was reported concerning the patterns across all measured symptoms, and comparative evidence is lacking to provide context for the reported outcomes. Data are still emerging, meaning the research provides context but not individual predictions.

Common questions about Карнифит (FAQ)

---

Q: What is the primary role of the active ingredient in Карнифит?

According to the official product information, the active ingredient, L-carnitine, is an amino acid derivative that plays a crucial role in cellular energy metabolism. Its primary function is described as transporting long-chain fatty acids into the mitochondria, which are the cell's main energy centers. This process helps the body utilize fat for energy production, as noted in the regulatory documents.

---

Q: Does Карнифит offer protective benefits to the heart (cardioprotective effect)?

Regulatory documents mention the potential for L-carnitine to support the heart muscle, suggesting a cardioprotective effect. This is associated with its fundamental role in optimizing cellular energy and metabolic processes in the heart. Official guidance indicates it may be considered for supportive therapy in managing certain heart-related conditions.

---

Q: Can Карнифит improve mental function or memory (nootropic effects)?

Official product information indicates that L-carnitine has been studied or used in supportive care for certain conditions involving the central nervous system. This is tied to its general metabolic support role, which ensures energy supply to all cells, including nerve cells. However, its primary indicated use is for treating carnitine deficiencies and supporting metabolism.

---

Q: Is Карнифит available for use in children?

Official information indicates that the active ingredient, L-carnitine, can be used in pediatric practice for specific conditions that require it. The use of this medication in children requires a specific medical necessity and is dependent on the diagnosis and the product's formulation. Regulatory documents confirm that professional guidance is necessary for its proper application in pediatric patients.

---

Q: Can I take Карнифит if I am undergoing dialysis (hemodialysis)?

According to the official product information, Карнифит is indicated for use in patients with secondary L-carnitine deficiency, a condition that can be associated with hemodialysis. The product's labeling notes its role in helping to replenish carnitine levels which may be lost during the dialysis process. Regulatory labeling specifies that administration in this context requires professional medical management.

---

How to Store and Dispose of Карнифит (L-Carnitine Injection)

Карнифит (L-Carnitine solution for infusion) must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F), with permitted short excursions up to 30 C (86 F). The solution must be protected from light and it is explicitly required not to freeze the product.

For stability and safety, the medicine should be kept in its original container and stored out of the sight and reach of children.

Disposal of any unused or expired portions of Карнифит must be handled in accordance with local requirements for pharmaceutical waste. Consumers are advised to utilize community drug take-back programs when available, rather than discarding the product in household trash or wastewater.